The Use of ADSCs as a Treatment for Chronic Stroke

脂肪組織衍生幹細胞 (ADSCs) 在動物中顯著改善了中風後神經功能，並未出現安全問題。這些幹細胞療法在減少中風後的神經損傷和改善神經行為方面，展現了臨床應用的潛力。

Chan, T. M., Harn, H. J., Lin, H. P., Chiu, S. C., Lin, P. C., Wang, H. I., Ho, L. I., Chuu, C. P., Chiou, T. W., Hsieh, A. C., Chen, Y. W., Ho, W. Y., & Lin, S. Z. (2014). The use of ADSCs as a treatment for chronic stroke. Cell transplantation, 23(4-5), 541–547.

https://doi.org/10.3727/096368914X678409

Therapeutic Effect of Ligustilide-Stimulated Adipose-Derived Stem Cells in a Mouse Thromboembolic Stroke Model

Ligustilide 處理過的脂肪來源幹細胞 (ADSCs) 在小鼠中風模型中，顯著提升了治療效果，相比未處理的ADSCs，改善效果更佳。Ligustilide 可有效增強幹細胞在中風治療的潛力。

Chi, K., Fu, R. H., Huang, Y. C., Chen, S. Y., Lin, S. Z., Huang, P. C., Lin, P. C., Chang, F. K., & Liu, S. P. (2016). Therapeutic Effect of Ligustilide-Stimulated Adipose-Derived Stem Cells in a Mouse Thromboembolic Stroke Model. Cell transplantation, 25(5), 899–912.

https://doi.org/10.3727/096368916X690539

Intracerebral transplantation of autologous adipose‐derived stem cells for chronic ischemic stroke: A phase I study

思益優 (GXNPC1) 在慢性中風患者中展現了顯著的神經功能改善：美國國家衛生院腦中風量表（NIHSS）改善了5至15分，巴氏量表提高了 25 至 50 分，且核磁共振（MRI）結果顯示患者腦梗塞區域縮小。6 個月追蹤期間無與藥物相關嚴重不良反應（SAE），治療顯示出良好的安全性和效果。

Chiu, T. L., Baskaran, R., Tsai, S. T., Huang, C. Y., Chuang, M. H., Syu, W. S., Harn, H. J., Lin, Y. C., Chen, C. H., Huang, P. C., Wang, Y. F., Chuang, C. H., Lin, P. C., & Lin, S. Z. (2022). Intracerebral transplantation of autologous adipose-derived stem cells for chronic ischemic stroke: A phase I study. Journal of tissue engineering and regenerative medicine, 16(1), 3–13.

https://doi.org/10.1002/term.3256

回到列表